Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 39, 2015, Pages E5381-E5390

  Davare, Monika A ^a,b   Vellore, Nadeem A ^c,d   Wagner, Jacob P ^a,b   Eide, Christopher A ^e,f   Goodman, James R ^e   Drilon, Alexander ^g   Deininger, Michael W ^c,d   O'Hare, Thomas ^c,d   Druker, Brian J ^e,f  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

ALK; Inhibitor; Kinase; ROS1; Structural modelling

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; AZD 3463; BRIGATINIB; CABOZANTINIB; CERITINIB; CRIZOTINIB; FORETINIB; PHOSPHOTRANSFERASE; PROTEIN ROS1; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ANILIDE; ANTINEOPLASTIC AGENT; ONCOPROTEIN; PROTEIN BINDING; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; QUINOLINE DERIVATIVE; ROS1 PROTEIN, HUMAN;

ARTICLE; BINDING SITE; DRUG DESIGN; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SENSITIVITY; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN DOMAIN; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; DRUG DEVELOPMENT; DRUG RESISTANCE; HUMAN; IMMUNOBLOTTING; IN VITRO STUDY; MOLECULAR MODEL; PHYSIOLOGY; PROCEDURES; PROTEIN CONFORMATION;

ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOBLOTTING; IN VITRO TECHNIQUES; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PYRAZOLES; PYRIDINES; QUINOLINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84942860475     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1515281112     Document Type: Article

References (77)

1. Druker BJ (2009) Perspectives on the development of imatinib and the future of cancer research. Nat Med 15(10): 1149-1152.
2. Druker BJ, et al.; IRIS Investigators (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23): 2408-2417.
3. Nowell PC, Hungerford DA (1960) Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 25: 85-109.
4. Shaw AT, Hsu PP, Awad MM, Engelman JA (2013) Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer 13(11): 772-787.
5. Grande E, Bolós MV, Arriola E (2011) Targeting oncogenic ALK: A promising strategy for cancer treatment. Mol Cancer Ther 10(4): 569-579.
6. Awad MM, Shaw AT (2014) ALK inhibitors in non-small cell lung cancer: Crizotinib and beyond. Clin Adv Hematol Oncol 12(7): 429-439.
7. Shaw AT, Engelman JA (2013) ALK in lung cancer: Past, present, and future. J Clin Oncol 31(8): 1105-1111.
8. Davies KD, Doebele RC (2013) Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res 19(15): 4040-4045.
9. Arai Y, et al. (2013) Mouse model for ROS1-rearranged lung cancer. PLoS One 8(2): e56010.
10. Charest A, et al. (2006) ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res 66(15): 7473-7481.
11. Saborowski A, et al. (2013) Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target. Proc Natl Acad Sci USA 110(48): 19513-19518.
12. Bergethon K, et al. (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30(8): 863-870.
13. Chin LP, Soo RA, Soong R, Ou SH (2012) Targeting ROS1 with anaplastic lymphoma kinase inhibitors: A promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol 7(11): 1625-1630.
14. Shaw AT, et al. (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368(25): 2385-2394.
15. Shaw AT, et al. (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371(21): 1963-1971.
16. O'Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ (2011) Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res 17(2): 212-221.
17. Yu HA, Riely GJ, Lovly CM (2014) Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Clin Cancer Res 20(23): 5898-5907.
18. Riely GJ, Politi KA, Miller VA, Pao W (2006) Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12(24): 7232-7241.
19. Doebele RC, et al. (2012) Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18(5): 1472-1482.
20. Heuckmann JM, et al. (2011) ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 17(23): 7394-7401.
21. Lovly CM, Pao W (2012) Escaping ALK inhibition: Mechanisms of and strategies to overcome resistance. Sci Transl Med 4(120): 120ps2.
22. Awad MM, et al. (2013) Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 368(25): 2395-2401.
23. Davare MA, et al. (2013) Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc Natl Acad Sci USA 110(48): 19519-19524.
24. Baron R, McCammon JA (2013) Molecular recognition and ligand association. Annu Rev Phys Chem 64: 151-175.
25. Dror RO, Dirks RM, Grossman JP, Xu H, Shaw DE (2012) Biomolecular simulation: A computational microscope for molecular biology. Annu Rev Biophys 41: 429-452.
26. Magalhaes A, Maigret B, Hoflack J, Gomes JN, Scheraga HA (1994) Contribution of unusual arginine-arginine short-range interactions to stabilization and recognition in proteins. J Protein Chem 13(2): 195-215.
27. Neves MA, Yeager M, Abagyan R (2012) Unusual arginine formations in protein function and assembly: Rings, strings, and stacks. J Phys Chem B 116(23): 7006-7013.
28. Soetens J-CMC, Chipot C, Jansen G, Ángyán JG, Maigret B (1997) Effect of polarizability on the potential of mean force of two cations: The guanidinium-guanidinium ion pair in water. J Phys Chem 101(50): 10910-10917.
29. Feixas F, Lindert S, Sinko W, McCammon JA (2014) Exploring the role of receptor flexibility in structure-based drug discovery. Biophys Chem 186: 31-45.
30. Amaro RE, Baron R, McCammon JA (2008) An improved relaxed complex scheme for receptor flexibility in computer-aided drug design. J Comput Aided Mol Des 22(9): 693-705.
31. Shewchuk L, et al. (2000) Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J Med Chem 43(1): 133-138.
32. Solomon VR, Lee H (2011) Quinoline as a privileged scaffold in cancer drug discovery. Curr Med Chem 18(10): 1488-1508.
33. Zhang Q, et al. (2014) Identification of type II inhibitors targeting BRAF using privileged pharmacophores. Chem Biol Drug Des 83(1): 27-36.
34. Qian F, et al. (2009) Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 69(20): 8009-8016.
35. Aronov AM, et al. (2007) Flipped out: Structure-guided design of selective pyrazolylpyrrole ERK inhibitors. J Med Chem 50(6): 1280-1287.
36. Atwell S, et al. (2004) A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J Biol Chem 279(53): 55827-55832.
37. Camidge DR, Pao W, Sequist LV (2014) Acquired resistance to TKIs in solid tumours: Learning from lung cancer. Nat Rev Clin Oncol 11(8): 473-481.
38. Choi YL, et al.; ALK Lung Cancer Study Group (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363(18): 1734-1739.
39. Chong CR, Jänne PA (2013) The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 19(11): 1389-1400.
40. O'Hare T, et al. (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65(11): 4500-4505.
41. Shah NP, et al. (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 117(9): 2562-2569.
42. Soverini S, et al. (2013) Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood 122(9): 1634-1648.
43. Zabriskie MS, et al. (2014) BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 26(3): 428-442.
44. Levinson NM, et al. (2006) A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol 4(5): e144.
45. Shan Y, et al. (2009) A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc Natl Acad Sci USA 106(1): 139-144.
46. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC (1999) Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 3(5): 629-638.
47. Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10(11): 760-774.
48. Gadgeel SM, et al. (2014) Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15(10): 1119-1128.
49. Gainor JF, et al. (2015) Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol 10(2): 232-236.
50. Shaw AT, et al. (2014) Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370(13): 1189-1197.
51. Cui JJ, et al. (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 54(18): 6342-6363.
52. Friboulet L, et al. (2014) The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 4(6): 662-673.
53. Sakamoto H, et al. (2011) CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19(5): 679-690.
54. Katayama R, et al. (2014) Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res 20(22): 5686-5696.
55. Davis MI, et al. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29(11): 1046-1051.
56. Wilson C, et al. (2015) Kinase dynamics: Using ancient protein kinases to unravel a modern cancer drug's mechanism. Science 347(6224): 882-886.
57. Zhao Z, et al. (2014) Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? ACS Chem Biol 9(6): 1230-1241.
58. Lovly CM, et al. (2011) Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 71(14): 4920-4931.
59. Katayama R, et al. (2015) Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clin Cancer Res 21(1): 166-174.
60. Bradeen HA, et al. (2006) Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: High efficacy of drug combinations. Blood 108(7): 2332-2338.
61. O'Hare T, et al. (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16(5): 401-412.
62. Smith CC, et al. (2012) Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485(7397): 260-263.
63. Epstein LF, Chen H, Emkey R, Whittington DA (2012) The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase. J Biol Chem 287(44): 37447-37457.
64. Sebaugh JL (2011) Guidelines for accurate EC50/IC50 estimation. Pharm Stat 10(2): 128-134.
65. Case DA, et al. (2012) AMBER 12 (University of California, San Fransisco).
66. Phillips JC, et al. (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26(16): 1781-1802.
67. Miyamoto S, Kollman PA (1992) Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models. J Comput Chem 13(8): 952-962.
68. Darden T, York D, Pedersen L (1993) Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems. J Chem Phys 98(12): 10089.
69. Martyna GJ, Tobias DJ, Klein ML (1994) Constant pressure molecular dynamics algorithms. J Chem Phys 101(5): 4177.
70. Pastor RW, Brooks BR, Szabo A (1988) An analysis of the accuracy of Langevin and molecular dynamics algorithms. Mol Phys 65(6): 1409-1419.
71. Roe DR, Cheatham TE (2013) PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput 9(7): 3084-3095.
72. Durrant JD, Votapka L, Sørensen J, Amaro RE (2014) POVME 2.0: An enhanced tool for determining pocket shape and volume characteristics. J Chem Theory Comput 10(11): 5047-5056.
73. Friesner RA, et al. (2006) Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49(21): 6177-6196.
74. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25(9): 1157-1174.
75. Bayly C, Cieplak P, Cornell W, Kollman P (1993) A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: The RESP model. J Phys Chem 97(40): 10269-10280.
76. Jorgensen WLCJ, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79: 926.
77. Joung IS, Cheatham TE, 3rd (2008) Determination of alkali and halide monovalent ion parameters for use in explicitly solvated biomolecular simulations. J Phys Chem B 112(30): 9020-9041.